-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, it is the financial report disclosure season of listed pharmaceutical companies.
As of now, most companies have basically released their 2021 transcripts.
Among them, there are some newly listed pharmaceutical companies, such as Chi-Med Pharmaceuticals, Dorui Pharmaceuticals, etc.
In addition, there are also some realizations.
Pharmaceutical companies that have been listed in many places have released their first financial reports.
On the whole, the word "profit" takes the lead
.
Keji Pharmaceutical: The annual performance loss after listing on the Hong Kong Stock Exchange has expanded Recently, Keji Pharmaceutical, a leading company focusing on the field of solid tumor cell therapy, disclosed the company's first financial report after landing on the Hong Kong Stock Exchange
.
The report shows that during the reporting period, the company achieved operating income of 25.
813 million yuan, a net loss attributable to the parent company of 4.
744 billion yuan, a year-on-year increase of 345.
88%, and basic earnings per share of -12.
26 yuan
.
According to public information, Keji Pharmaceuticals, founded in 2014, is a biopharmaceutical company with operations in China and the United States, focusing on innovative CAR-T cell therapy for the treatment of hematological malignancies and solid tumors
.
On June 18, 2021, Keji Pharmaceuticals landed on the Hong Kong stock market with much anticipation, becoming another Chinese cell therapy company in the secondary market
.
Dorui Medicine: Steady annual performance after GEM listing Dorui Pharmaceutical disclosed the company's first financial report after its listing on the evening of March 24.
The report shows that the company will achieve operating income of 530 million yuan in 2021, a year-on-year increase of 8.
05%, maintaining a stable growth
.
It is reported that in 2021, the market share of the company's core product, Sodium Acetate Ringer's Injection, will be at the forefront.
.
According to public information, Dorui Medicine was established in 2016 and successfully landed on the GEM in September 2021
.
The company is mainly engaged in the research and development, production and sales of chemical preparations and their APIs, and focuses on the layout of product pipelines in the perioperative period and emergency rescue.
.
Chi-Med Pharmaceutical: The first annual report after listing on the Hong Kong Stock Exchange reported that Chi-Med Pharmaceutical’s 2021 financial report showed that the total revenue for the year was US$356.
1 million, a year-on-year increase of 56%; the company’s attributable net loss was US$195 million, an increase of 54.
81% year-on-year; research and development expenses 299.
1 million US dollars, a year-on-year increase of 71%
.
During the reporting period, the growth of the company's total revenue was mainly driven by the commercialization progress of three self-developed oncology drugs, namely Aiyoute®, Suteda® and Voressa®
.
According to public information, Chi-Med was established in 2000 and is a global biopharmaceutical company in the commercialization stage, focusing on the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immune diseases
.
The company was officially listed on the Hong Kong Stock Exchange on June 30, 2021
.
It is worth mentioning that the company has previously been listed on the London Stock Exchange and NASDAQ in the United States
.
BeiGene: The first financial report after the listing of the three places is remarkable.
On the evening of February 25, BeiGene disclosed the first financial report after the listing of the three places: the revenue in 2021 is 1.
176 billion US dollars, and the revenue in the same period last year was 308 million US dollars.
, The reason for the sharp increase in revenue is that the product cooperation revenue is as high as 543 million US dollars; the net loss in 2021 will be 1.
4 billion US dollars, narrowing 13% year-on-year
.
But the company has plenty of cash on hand, adding more than $4 billion to its cash hoard in 2021
.
Founded in 2010, BeiGene is a science-based global biotechnology company focused on developing innovative, affordable medicines designed to improve outcomes and improve access to medicines for patients around the world
.
By strengthening independent research and development capabilities and cooperation, the company accelerates the development of diversified and innovative drug pipelines, is committed to comprehensively improving drug accessibility for more than 2 billion people around the world by 2030, and strives to achieve the goal of "hundreds of innovative drugs, helping the world and benefiting the people".
vision
.
The company was listed on Nasdaq in the United States in 2016 and listed on the Hong Kong Stock Exchange in 2018
.
On December 15, 2021, BeiGene was listed on the Science and Technology Innovation Board again, becoming the world's first biotech company listed on the Nasdaq, the Hong Kong Stock Exchange and the Shanghai Stock Exchange.
.
"Testing and Calibration of Dry Body Temperature Calibrators" is about to be broadcast, welcome to sign up Disclaimer: In any case, the information or opinions expressed in this article do not constitute investment advice to anyone
.
As of now, most companies have basically released their 2021 transcripts.
Among them, there are some newly listed pharmaceutical companies, such as Chi-Med Pharmaceuticals, Dorui Pharmaceuticals, etc.
In addition, there are also some realizations.
Pharmaceutical companies that have been listed in many places have released their first financial reports.
On the whole, the word "profit" takes the lead
.
Keji Pharmaceutical: The annual performance loss after listing on the Hong Kong Stock Exchange has expanded Recently, Keji Pharmaceutical, a leading company focusing on the field of solid tumor cell therapy, disclosed the company's first financial report after landing on the Hong Kong Stock Exchange
.
The report shows that during the reporting period, the company achieved operating income of 25.
813 million yuan, a net loss attributable to the parent company of 4.
744 billion yuan, a year-on-year increase of 345.
88%, and basic earnings per share of -12.
26 yuan
.
According to public information, Keji Pharmaceuticals, founded in 2014, is a biopharmaceutical company with operations in China and the United States, focusing on innovative CAR-T cell therapy for the treatment of hematological malignancies and solid tumors
.
On June 18, 2021, Keji Pharmaceuticals landed on the Hong Kong stock market with much anticipation, becoming another Chinese cell therapy company in the secondary market
.
Dorui Medicine: Steady annual performance after GEM listing Dorui Pharmaceutical disclosed the company's first financial report after its listing on the evening of March 24.
The report shows that the company will achieve operating income of 530 million yuan in 2021, a year-on-year increase of 8.
05%, maintaining a stable growth
.
It is reported that in 2021, the market share of the company's core product, Sodium Acetate Ringer's Injection, will be at the forefront.
.
According to public information, Dorui Medicine was established in 2016 and successfully landed on the GEM in September 2021
.
The company is mainly engaged in the research and development, production and sales of chemical preparations and their APIs, and focuses on the layout of product pipelines in the perioperative period and emergency rescue.
.
Chi-Med Pharmaceutical: The first annual report after listing on the Hong Kong Stock Exchange reported that Chi-Med Pharmaceutical’s 2021 financial report showed that the total revenue for the year was US$356.
1 million, a year-on-year increase of 56%; the company’s attributable net loss was US$195 million, an increase of 54.
81% year-on-year; research and development expenses 299.
1 million US dollars, a year-on-year increase of 71%
.
During the reporting period, the growth of the company's total revenue was mainly driven by the commercialization progress of three self-developed oncology drugs, namely Aiyoute®, Suteda® and Voressa®
.
According to public information, Chi-Med was established in 2000 and is a global biopharmaceutical company in the commercialization stage, focusing on the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immune diseases
.
The company was officially listed on the Hong Kong Stock Exchange on June 30, 2021
.
It is worth mentioning that the company has previously been listed on the London Stock Exchange and NASDAQ in the United States
.
BeiGene: The first financial report after the listing of the three places is remarkable.
On the evening of February 25, BeiGene disclosed the first financial report after the listing of the three places: the revenue in 2021 is 1.
176 billion US dollars, and the revenue in the same period last year was 308 million US dollars.
, The reason for the sharp increase in revenue is that the product cooperation revenue is as high as 543 million US dollars; the net loss in 2021 will be 1.
4 billion US dollars, narrowing 13% year-on-year
.
But the company has plenty of cash on hand, adding more than $4 billion to its cash hoard in 2021
.
Founded in 2010, BeiGene is a science-based global biotechnology company focused on developing innovative, affordable medicines designed to improve outcomes and improve access to medicines for patients around the world
.
By strengthening independent research and development capabilities and cooperation, the company accelerates the development of diversified and innovative drug pipelines, is committed to comprehensively improving drug accessibility for more than 2 billion people around the world by 2030, and strives to achieve the goal of "hundreds of innovative drugs, helping the world and benefiting the people".
vision
.
The company was listed on Nasdaq in the United States in 2016 and listed on the Hong Kong Stock Exchange in 2018
.
On December 15, 2021, BeiGene was listed on the Science and Technology Innovation Board again, becoming the world's first biotech company listed on the Nasdaq, the Hong Kong Stock Exchange and the Shanghai Stock Exchange.
.
"Testing and Calibration of Dry Body Temperature Calibrators" is about to be broadcast, welcome to sign up Disclaimer: In any case, the information or opinions expressed in this article do not constitute investment advice to anyone
.
